Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis

BMC Gastroenterology

Volumn 11, Issue , 2011, Pages

  Kverka, Miloslav ^a   Rossmann, Pavel ^a   Tlaskalova Hogenova, Helena ^a   Klimesova, Klara ^a   Jharap, Bindia ^b   de Boer, Nanne K ^b   Vos, Rene M ^b   van Bodegraven, Adriaan A ^b   Lukas, Milan ^c   Mulder, Chris J ^b  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Clinical and Research Center for Inflammatory Bowel Disease ISCARE Lighthouse   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6; PHOSPHATE BUFFERED SALINE; PLACEBO; TIOGUANINE; DEXTRAN SULFATE; TRANSFORMING GROWTH FACTOR BETA;

ACUTE COLITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC COLITIS; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HISTOPATHOLOGY; IMMUNOMODULATION; LIVER HISTOLOGY; LIVER TOXICITY; LOW DRUG DOSE; MOUSE; NONHUMAN; SPLEEN; TOXICITY TESTING; WEIGHT CHANGE; ACUTE DISEASE; ANALYSIS OF VARIANCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; COLON; DRUG EFFECT; LIVER; METABOLISM; PATHOLOGY; WEIGHT REDUCTION;

ACUTE DISEASE; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; AZATHIOPRINE; CHRONIC DISEASE; COLITIS; COLON; DEXTRAN SULFATE; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-6; LIVER; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; T-LYMPHOCYTES, HELPER-INDUCER; THIOGUANINE; TRANSFORMING GROWTH FACTOR BETA; WEIGHT LOSS;

EID: 79955567369     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-11-47     Document Type: Article

References (39)

1. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678. 10.1136/gut.37.5.674, 1382873, 8549944.
2. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50:485-489. 10.1136/gut.50.4.485, 1773162, 11889067.
3. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980, 302:981-987. 10.1056/NEJM198005013021801, 6102739.
4. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003, 111:1133-1145. 152932, 12697733.
5. Thomas CW, Myhre GM, Tschumper R, Sreekumar R, Jelinek D, McKean DJ, Lipsky JJ, Sandborn WJ, Egan LJ. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther 2005, 312:537-545.
6. de Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 2003, 69-72.
7. Jharap B, Seinen ML, de Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJ, van Bodegraven AA. Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010, 19:1541-1549.
8. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995, 123:132-142.
9. de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007, 4:686-694.
10. Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange EF. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment Pharmacol Ther 2003, 17:1459-1464. 10.1046/j.1365-2036.2003.01590.x, 12823147.
11. Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298-303. 10.1016/S0016-5085(03)00938-7, 12891528.
12. Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH, Abreu MT, Tran T, Martin P, Vierling JM, Targan SR. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 2004, 28:1204-1211. 10.1097/01.pas.0000128665.12063.97, 15316320.
13. Seiderer J, Zech CJ, Reinisch W, Lukas M, Diebold J, Wrba F, Teml A, Chalupna P, Stritesky J, Schoenberg SO, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005, 43:303-309. 10.1016/j.jhep.2005.02.051, 15964660.
14. de Boer NK, Derijks LJ, Gilissen LP, Hommes DW, Engels LG, de-Boer SY, den Hartog G, Hooymans PM, Makelburg AB, Westerveld BD, et al. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol 2005, 11:5540-5544.
15. Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm Bowel Dis 2008, 14:1399-1405. 10.1002/ibd.20492, 18521912.
16. Derijks LJ, Gilissen LP, de Boer NK, Mulder CJ. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?. J Hepatol 2006, 44:821-822. 10.1016/j.jhep.2005.11.049, 16487623.
17. Gilissen LP, Derijks LJ, Driessen A, Bos LP, Hooymans PM, Stockbrugger RW, Engels LG. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?. Dig Liver Dis 2007, 39:156-159. 10.1016/j.dld.2006.10.007, 17188950.
18. Qasim A, McDonald S, Sebastian S, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease. Scand J Gastroenterol 2007, 42:194-199. 10.1080/00365520600825166, 17327939.
19. De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, Cuesta MA, Meuwissen SG, Van Nieuwkerk CM, Van Bodegraven AA. Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand J Gastroenterol 2008, 43:604-608. 10.1080/00365520701800266, 18415755.
20. Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004, 26:311-318. 10.1097/00007691-200406000-00016, 15167634.
21. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993, 69:238-249.
22. Kverka M, Zakostelska Z, Klimesova K, Sokol D, Hudcovic T, Hrncir T, Rossmann P, Mrazek J, Kopecny J, Verdu EF, Tlaskalova-Hogenova H. Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol 2011, 163:250-259. 10.1111/j.1365-2249.2010.04286.x, 21087444.
23. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, Van Rees EP. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998, 114:385-391. 10.1046/j.1365-2249.1998.00728.x, 1905133, 9844047.
24. Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol In Vitro 2008, 22:632-642. 10.1016/j.tiv.2007.12.004, 18222062.
25. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modigliani R, Touze Y, Catala P, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000, 118:1025-1030. 10.1016/S0016-5085(00)70354-4, 10833476.
26. Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993, 69:577-579. 10.1136/adc.69.5.577, 1029622, 8257179.
27. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904-915. 10.1053/gast.2002.32420, 11910342.
28. Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Mate J. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007, 13:1106-1114. 10.1002/ibd.20160, 17455203.
29. Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, Cadiot G, Bouhnik Y, De Vos M, Boureille A, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007, 56:1404-1409. 10.1136/gut.2006.114363, 2000290, 17504943.
30. Holtmann M, Schreiner O, Kohler H, Denzer U, Neurath M, Galle PR, Hohler T. Veno-occlusive disease (VOD) in Crohn's disease (CD) treated with azathioprine. Dig Dis Sci 2003, 48:1503-1505. 10.1023/A:1024755521423, 12924643.
31. Russmann S, Kaye JA, Jick SS, Jick H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol 2005, 60:76-82. 10.1111/j.1365-2125.2005.02370.x, 1884907, 15963097.
32. de Boer NK, Zondervan PE, Gilissen LP, den Hartog G, Westerveld BD, Derijks LJ, Bloemena E, Engels LG, van Bodegraven AA, Mulder CJ. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig Liver Dis 2008, 40:108-113. 10.1016/j.dld.2007.10.013, 18083079.
33. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990, 11:787-797. 10.1002/hep.1840110512, 2189821.
34. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986, 83:4167-4171. 10.1073/pnas.83.12.4167, 323692, 2424019.
35. Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis 2001, 7:16-26.
36. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238. 10.1038/nature04753, 16648838.
37. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234. 10.1038/nature04754, 16648837.
38. Deibert P, Dilger K, Fischer C, Hofmann U, Nauck S, Stoelben S, Kreisel W. High variation of tioguanine absorption in patients with chronic active Crohn's disease. Aliment Pharmacol Ther 2003, 18:183-189. 10.1046/j.1365-2036.2003.01652.x, 12869078.
39. Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001, 7:181-189. 10.1097/00054725-200108000-00001, 11515842.